Table of Contents
SECURITIES AND EXCHANGE COMMISSION
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of October
Commission File Number 000-31062
Oncolytics Biotech Inc.
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
| Form 20-F o | Form 40-F þ |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
| Yes o | No þ |
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82 -
| Signatures | ||||||||
| Press Release | ||||||||
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Oncolytics
Biotech Inc. (Registrant) |
||||
| Date: October 19, 2005 | By: | /s/ Doug Ball
Doug Ball Chief Financial Officer |
||
Table of Contents
 |
210, 1167 Kensington Crescent NW Calgary, Alberta Canada T2N 1X7 |
Canadian Phase I Recurrent Malignant Glioma Clinical Trial
Oncolytics is a Calgary-based biotechnology company focused on the development of REOLYSIN®, its proprietary formulation of the human reovirus, as a potential cancer therapeutic. Oncolytics’ researchers have demonstrated that the reovirus is able to selectively kill cancer cells and, in vitro, kill human cancer cells that are derived from many types of cancer including breast, bladder, prostate, pancreatic and brain tumours, and have also demonstrated successful cancer treatment results in a number of animal models. Previous Phase I clinical trial results have indicated that REOLYSIN® was well tolerated and that the reovirus demonstrated activity in tumours injected with REOLYSIN®.
Table of Contents
FOR FURTHER INFORMATION PLEASE CONTACT:
| Oncolytics Biotech Inc. | The Equicom Group | |
| Dr. Brad Thompson | Joanna Longo | |
| 210, 1167 Kensington Cr NW | 20 Toronto Street | |
| Calgary, Alberta T2N 1X7 | Toronto, Ontario M5C 2B8 | |
| Tel: 403.670.7377 | Tel: 416.815.0700 ext. 233 | |
| Fax: 403.283.0858 | Fax: 416.815.0080 | |
| www.oncolyticsbiotech.com | jlongo@equicomgroup.com | |
| The Investor Relations Group | RenMark Financial Communications | |
| John Nesbett or Damian McIntosh | John Boidman | |
| 11 Stone Street, 3rd Floor | 2080 Rene Levesque Blvd. W. | |
| New York, NY 10004 | Montreal, PQ H3H 1R6 | |
| Tel: 212.825.3210 | Tel: 514.939.3989 | |
| Fax: 212.825.3229 | Fax: 514.939.3717 | |
| dmcintosh@investorrelationsgroup.com | jboidman@renmarkfinancial.com |
-30-